BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.

PAVLASOVÁ, Gabriela, Marek BORSKÝ, Veronika SVOBODOVÁ, Kateřina MUSILOVÁ, Kateřina ČERNÁ, Václav ŠEDA, Jitka NOVOTNÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Marek MRÁZ. BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo. In 22nd EHA Annual Congress; Madrid, Spain, červen 2017 in Haematologica 2017. 2017.

Basic information

• Original name: BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.
• Authors: PAVLASOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Veronika SVOBODOVÁ (203 Czech Republic), Kateřina MUSILOVÁ (203 Czech Republic, belonging to the institution), Kateřina ČERNÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Jitka NOVOTNÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek MRÁZ (203 Czech Republic, belonging to the institution).
• Edition: 22nd EHA Annual Congress; Madrid, Spain, červen 2017 in Haematologica 2017, 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14740/17:00095680
• Organization unit: Central European Institute of Technology
• Keywords in English: BCR; CLL; rituximab
• Tags: MEDGENET, rivok

Abstract

BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo., BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo.

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1106/2016, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

• MUNI/H/0865/2016, interní kód MU: Name: Coding and Non-coding RNA Networks that Regulate B Cell Receptor Signalling: Implications for Combinatorial Therapy

Investor: Masaryk University, Individual High risk/high gain projects

• NV16-29622A, research and development project: Name: VLIV TERAPEUTICKÉ INHIBICE BCR SIGNALIZACE NA GENOVOU EXPRESI U B BUNĚČNÝCH MALIGNIT A JEJÍ PROGNOSTICKÝ A PREDIKTIVNÍ VÝZNAM
• 692298, interní kód MU: Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)

Investor: European Union, Spreading excellence and widening participation